Stephen J.LurieMD, PhD, Senior Editor
To the Editor: The WHI trial1 was stopped early because of an increased risk of breast cancer among women receiving the estrogen-progestin combination. The age-adjusted incidence rates for breast cancer from 1988-1992 for women aged 50 to 79 years, comparable with WHI, were 24 to 47 per 10 000 person-years.2 The numbers of cases in the control and intervention group were within the normal range of healthy US women, indicating no increased risk in the intervention group.
Franke HR. Risks of Postmenopausal Hormone Replacement. JAMA. 2002;288(22):2821. doi:10.1001/jama.288.22.2821-JLT1211-1-6